Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on May 14, 2021 2:03pm
101 Views
Post# 33204498

RE:RE:RE:RE:Symposium

RE:RE:RE:RE:Symposium

My point is they tried the institutional investors yet got screwed with the "OO" followed by not a single question from legacy analysts during last earning call, followed by bogus reports from the analysts  so that strategy failed miserably. Now they can keep digging a deeper hole or acknowledge their past mistakes and adapt to the reality. That's the start! 
The retail frenzy in the market isn't going away and that's the new normal going back to CYDY they realized how to utilize the opportunity their market value appreciated by 300 per cent between December 2019 and February 2020 before their wonder drug was even considered for covid19.
We can say what we want but the cold and ugly reality is what they did worked and what THTX did and still doing didn't.
My point re the symposium was why can't they do similar efforts to sell their programs attending  OTHER conferences preferably retail oriented conferences.
We have a daily volume of about 30 40 k in Canada so obviously there  is very little interest from investors and that is tragic for a company who has achieved many milestones during last two years. 



qwerty22 wrote:

"They are trying to bring awareness to their science but the net effect would be much higher if it was targeting bigger audience."

I don't believe that is what they are trying to do with this symposium. They are trying to talk to prescribers in order to boost sales. They don't need to go on Reddit and talk to retail investors to do that, that would be a waste of time. Where is the bigger platform for talking to HIV prescribers?

I think the difference between you and me (on this issue) is you're seeing every aspect of their business thru the single lens of the failure to engage retail investors. "What's the point in engaging at the US premier HIV prescriber conference when they aren't on Reddit flogging their science?" seems to be your point. It doesn't make sense to me, it's like you think there's only one thing to fix here and every activity needs to revolve around fixing that problem. I don't want them to run the business like that.

 

scarlet1967 wrote: The difference between me and you is the fact you see success in running a business solely as success in running the trials.
I see the success in running the business as a result of success in running all parts of it, including cost control, strategic planning, marketing, sales and competent leadership among others.
 

 

qwerty22 wrote:

It's clinical, at a clinical conference. They are talking to the people that prescribe the drug. This is about clinical engagement and sales not what you want it to be. Let them run their business.

About ACTHIV

The American Conference for the Treatment of HIV (ACTHIV) is the premier conference in the US dedicated exclusively to the frontline care team and its members who are caring for persons living with or at risk of acquiring HIV. The conference delivers information on new developments and research findings that can be rapidly translated and directly applied to the clinical setting.

 

 

scarlet1967 wrote:

 

I think the purpose of it is to discuss both lipodystrophy and NASH. Would it be wonderful to get some KOLs together and arrange for a conference on a well followed platform to discuss their programs. They are trying to bring awareness to their science but the net effect would be much higher if it was targeting bigger audience.
https://www.linkedin.com/posts/theratechnologies-inc_symposium-acthiv-acthiv2021-activity-6798957933863538688-99CH


 

 




<< Previous
Bullboard Posts
Next >>